4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms

Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms

Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma (ALL/LBL) is a heterogeneous group of aggressive hematologic malignancies characterized by the clonal proliferation, arrest of differentiation, and accumulation of immature lymphoid progenitor cells (lymphoblasts) of either B-cell or T-cell lineage in the bone marrow, peripheral blood, and extramedullary sanctuary sites.

                 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
                                  │
         ┌────────────────────────┴────────────────────────┐
         ▼                                                 ▼
  B-CELL PRECURSOR ALL (B-ALL)                      T-CELL PRECURSOR ALL (T-ALL)
  • 80–85% of cases; peak age 2–5 yrs               • 15–20% of cases; adolescent males
  • Immunophenotype: CD19+, CD22+, CD79a+,          • Immunophenotype: cyCD3+ (lineage),
    Pax-5+, TdT+, CD34+, CD10 (CALLA)+                CD7+ (early), CD2+, CD5+, CD1a+, TdT+
  • Genetics:                                       • Clinical: Anterior mediastinal mass,
    - Favorable: Hyperdiploidy, ETV6::RUNX1           high WBC count (>100 x 10^9/L), rapid
    - Unfavorable: BCR::ABL1 (p190), KMT2A          • Cytochemistry: Focal polar Acid Phosphatase

---

1. Epidemiology & Clinical Manifestations

Epidemiological Patterns

• B-Lymphoblastic Leukemia (B-ALL): Represents approximately $80\text{ to }85%$ of childhood ALL cases. It is the single most common childhood malignancy, exhibiting a sharp peak in incidence between 2 and 5 years of age. A second, smaller incidence rise occurs in adults over 50 years of age.
• T-Lymphoblastic Leukemia (T-ALL): Accounts for $15\text{ to }20%$ of ALL cases. It demonstrates a distinct demographic predilection for adolescent and young adult males ($M:F \approx 3:1$).

Clinical Presentation & Sanctuary Sites

1. Bone Marrow Replacement (Pancytopenia): Rapid expansion of lymphoblasts within medullary spaces suppresses normal hematopoiesis, manifesting as:
   • Severe Anemia: Pallor, fatigue, lethargy, exertional dyspnea.
   • Thrombocytopenia: Petechiae, ecchymoses, mucosal epistaxis, gingival hemorrhage.
   • Neutropenia: Recurrent bacterial and fungal infections, fever of unknown origin.
2. Musculoskeletal Symptoms: Severe bone pain, arthralgias, refusal to bear weight, and limping in young children, resulting from leukemic expansion stretching the periosteum.
3. Extramedullary Organ Involvement: Generalized painless lymphadenopathy, marked hepatosplenomegaly, and soft tissue infiltration.
4. Sanctuary Sites: Anatomical compartments shielded from systemic chemotherapy by physiological barriers:
   • Central Nervous System (CNS): Manifests as headache, vomiting, papilledema, and cranial nerve palsies (cranial nerves VII and VI). Diagnostic criteria require cytocentrifugation of cerebrospinal fluid (CSF) demonstrating lymphoblasts.
   • Testes: Painless, firm, unilateral or bilateral testicular enlargement; a classic site of late extramedullary relapse.
5. T-ALL Mediastinal Syndrome: T-ALL characteristically arises within the thymus, presenting with an anterior mediastinal mass that compresses the trachea and superior vena cava, causing dyspnea, wheezing, orthopnea, and superior vena cava (SVC) syndrome (facial edema, jugular venous distention), accompanied by marked leukocytosis ($>100 \times 10^9\text{/L}$).

---

2. Lymphoblast Cytomorphology vs. Myeloblast Cytomorphology

Distinguishing lymphoblasts from myeloblasts on Wright-Giemsa stained films is the initial critical step in diagnostic triage:

                      BLAST CYTOMORPHOLOGY COMPARISON

         [ LYMPHOBLAST ]                             [ MYELOBLAST ]
  • Size: 10–18 µm (Smaller)                  • Size: 15–20 µm (Larger)
  • N:C Ratio: Very high (>4:1, scant rim)    • N:C Ratio: High (Moderate cytoplasm)
  • Chromatin: Dense, condensed, smooth       • Chromatin: Delicate, fine, "lacey"
  • Nucleoli: Inconspicuous / Absent (0–2)    • Nucleoli: 2 to 5 distinct, prominent
  • Cytoplasm: Scant light blue, agranular    • Cytoplasm: Moderate basophilic
  • AUER RODS: STRICTLY ABSENT (0%)           • AUER RODS: PRESENT in 30–50%

---

3. Lineage Immunophenotyping by Flow Cytometry

Definitive lineage assignment, developmental staging, and minimal residual disease (MRD) monitoring require multiparameter flow cytometric immunophenotyping:

                     IMMUNOPHENOTYPIC SUBTYPES OF ALL
                                    │
         ┌──────────────────────────┴──────────────────────────┐
         ▼                                                     ▼
  [ B-CELL PRECURSOR ALL ]                              [ T-CELL ALL ]
  • Pan-B: CD19, CD22, CD79a, Pax-5                     • Lineage-Defining: cyCD3
  • Immature: CD34, TdT, CD10 (CALLA)                   • Pan-T: CD7 (earliest), CD2, CD5
  • Developmental Stages:                               • Cortical: CD1a
    - Pro-B: CD10-                                      • Immature: CD4/CD8 double positive
    - Common B: CD10+ (CALLA+)                            or double negative, TdT+
    - Pre-B: Cytoplasmic mu+ (cmu+), sIg-               • Mature: Surface CD3+
    - Mature B: Surface Ig+ (kappa/lambda restricted)

1. B-Lymphoblastic Leukemia (B-ALL) Immunophenotypic Cascade

• Pan-B Lineage Markers: CD19, CD22, CD79a, and the master B-cell transcription factor PAX-5. CD20 expression is variable and acquires intensity during maturation.
• Immature / Progenitor Antigens: CD34, Terminal Deoxynucleotidyl Transferase (TdT), and CD10 (CALLA - Common Acute Lymphoblastic Leukemia Antigen).
• Sequential Developmental Stages:
  1. Pro-B ALL (Early Pre-B / FAB L1): CD19+, CD79a+, cyCD22+, TdT+, CD34+, CD10-negative. Highly correlated with KMT2A (11q23.3) translocations in infants.
  2. Common B-ALL: CD19+, CD79a+, CD10-positive (CALLA+), TdT+, CD34+. Represents the vast majority (~70%) of childhood B-ALL and carries the best general prognosis.
  3. Pre-B ALL: CD19+, CD10+, cytoplasmic immunoglobulin $\mu$ heavy chain positive ($c\mu^+$), surface immunoglobulin negative ($\text{sIg}^-$), TdT+.
  4. Mature B-ALL (Burkitt-type Leukemia): Surface immunoglobulin positive ($\text{sIg}^+$) with light chain restriction ($\kappa$ or $\lambda$), CD19+, CD20+, CD10+, TdT negative or weak. Characterized by $t(8;14)(q24;q32)$ MYC::IGH fusion.

2. T-Lymphoblastic Leukemia (T-ALL) Immunophenotypic Profile

• Lineage-Defining Antigen: Cytoplasmic CD3 ($\text{cyCD3}$) is the essential, lineage-specific marker that definitively confirms T-cell commitment; surface CD3 (sCD3) appears later in thymic ontogeny.
• Pan-T Antigens: CD7 (the earliest and most sensitive pan-T marker, present throughout all stages), CD2, and CD5.
• Thymocyte Maturation Markers: CD1a (marker of cortical thymocytes), CD4 and CD8 double-positive ($CD4^+CD8^+$) or double-negative ($CD4^-CD8^-$), and TdT positive.
• Early T-cell Precursor (ETP-ALL): High-risk subtype defined by CD1a(-), CD8(-), CD5(weak $<75%$ or absent), with co-expression of one or more myeloid/stem cell markers (CD34, CD117, HLA-DR, CD13, CD33).

---

4. Cytogenetic and Molecular Risk Stratification in ALL

Chromosomal and molecular abnormalities are the primary determinants of risk stratification and therapy intensity in ALL:

                      CYTOGENETIC STRATIFICATION IN ALL
                                    │
         ┌──────────────────────────┴──────────────────────────┐
         ▼                                                     ▼
[ FAVORABLE PROGNOSIS ]                               [ UNFAVORABLE PROGNOSIS ]
• Hyperdiploidy (>50 Chromosomes)                     • BCR::ABL1 [t(9;22) Minor Breakpoint p190]
• ETV6::RUNX1 [t(12;21)]                              • KMT2A (MLL) Rearranged [t(4;11)]
  - Most common pediatric fusion (~25%)                 - Infant ALL (<1 yr), Pro-B (CD10-)
  - Excellent response to chemotherapy                • Hypodiploidy (<44 Chromosomes)
  - Cure rate >90%                                    • TCF3::HLF [t(17;19)]

Critical Board Contrast — Philadelphia Chromosome Breakpoints: In Chronic Myeloid Leukemia (CML), the translocation breakpoint occurs in the major breakpoint cluster region (M-bcr), producing a 210-kDa oncoprotein (p210). In contrast, in Philadelphia-positive ALL (Ph+ ALL), the breakpoint occurs in the minor breakpoint cluster region (m-bcr), producing a 190-kDa oncoprotein (p190) in $>70%$ of cases.

---

5. Cytochemical Profile of ALL

While flow cytometry has superseded cytochemistry for detailed subtyping, specific cytochemical reactions remain high-yield on certification exams:

                      ALL CYTOCHEMICAL PROFILE

  ┌─────────────────────────────────────────────────────────────┐
  │ 1. Terminal Deoxynucleotidyl Transferase (TdT):             │
  │    • Nuclear enzyme; POSITIVE in >95% of B-ALL and T-ALL    │
  │    • Strictly negative in mature B-cells and AML            │
  │ 2. Periodic Acid-Schiff (PAS):                              │
  │    • "CHUNKY BLOCK" cytoplasmic positivity against clear   │
  │      background in 50–70% of lymphoblasts (glycogen)        │
  │ 3. Myeloperoxidase (MPO) & Sudan Black B (SBB):             │
  │    • STRICTLY NEGATIVE (excludes myeloid lineage)           │
  │ 4. Acid Phosphatase (AP):                                   │
  │    • T-ALL: FOCAL POLAR (PARANUCLEAR / GOLGI) DOT POSITIVE  │
  │    • B-ALL: Negative or weak diffuse                        │
  └─────────────────────────────────────────────────────────────┘

1. Terminal Deoxynucleotidyl Transferase (TdT): A template-independent DNA polymerase that adds non-templated N-nucleotides to V-D-J gene segments during TCR and immunoglobulin heavy chain gene rearrangement. Demonstrates strong nuclear positivity in $>95%$ of precursor B-ALL and T-ALL lymphoblasts, but is negative in mature B-cell malignancies (Burkitt leukemia), AML, and non-hematopoietic tumors.
2. Periodic Acid-Schiff (PAS): Stains intracellular glycogen and carbohydrate macromolecules. Approximately 50–70% of ALL cases display classic coarse "chunky block" or granular cytoplasmic positivity against a completely clear background, contrasting with the diffuse pink blush seen in maturing granulocytes.
3. Myeloperoxidase (MPO) and Sudan Black B (SBB): Strictly negative in ALL, providing unequivocal distinction from AML.
4. Acid Phosphatase (AP): In T-ALL, the lysosomal enzyme acid phosphatase is localized to the Golgi apparatus, producing a diagnostic focal, polar, paranuclear dot-like precipitate, whereas B-ALL is negative or weakly diffuse.